Articles related to HIV

Pharmacists are emerging as key players in expanding PrEP access, offering a unique opportunity to close the gap in HIV prevention. Learn how this shift could help us meet national HIV prevention goals.

The recent phase 3 trial on pitavastatin’s effectiveness in HIV-infected patients opens new avenues in cardiovascular disease prevention within this demographic. Physicians may find the detailed insights on risk reduction and side effects beneficial in tailoring personalized care strategies.

Single-tablet regimen (STR) coverage under qualified health plans (QHPs) varies widely across the US. Although bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) coverage has grown over time, many QHPs in priority jurisdictions for the Ending the HIV Epidemic (EHE) have coinsurance requirements. Delay in QHP coverage and benefit design may hinder access to new antiretroviral treatment (ART) regimens.

Other than anterior cervical and occipital lymphadenopathy, the physical examination and vitals are unremarkable. The patient is also requesting HIV pre-exposure prophylaxis initiation. HIV testing negative. What’s the best management?

Sunlenca (lenacapavir), which comes in 300 mg tablets and a 463.5 mg/1.5 mL injection, provides doctors with a long-needed twice-yearly option for patients with complicated past treatment histories who would otherwise have few treatment options.

A trio of posters look at clinical effectiveness fostemsavir for multidrug-resistant patients, real-world efficacy of the dolutegravir/lamivudine combination as a switch strategy, and a newer drug in the pipeline, islatravir prodrug BRII-732.